Image

Melanoma Research

Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma”
09/18/2021

Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma

LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer”
08/25/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 24, 2021  Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin”
07/22/2021

FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin

July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Gut Microbes Signal Response to Immune Therapy in Melanoma”
07/12/2021

Gut Microbes Signal Response to Immune Therapy in Melanoma

(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients”
06/30/2021

EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients

Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma”
06/15/2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

June 14, 2021 08:03 AM Eastern Daylight Time  | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Alkermes’s disappointment hones melanoma niche focus”
06/04/2021

Alkermes’s disappointment hones melanoma niche focus

June 04, 2021  | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/18/2021

Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma

LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Featured image for “Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
08/25/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 24, 2021  Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
Featured image for “Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/22/2021

FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin

July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Featured image for “FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/12/2021

Gut Microbes Signal Response to Immune Therapy in Melanoma

(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
Featured image for “Gut Microbes Signal Response to Immune Therapy in Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/30/2021

EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients

Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
Featured image for “EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/15/2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

June 14, 2021 08:03 AM Eastern Daylight Time  | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
Featured image for “Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
06/04/2021

Alkermes’s disappointment hones melanoma niche focus

June 04, 2021  | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
Featured image for “Alkermes’s disappointment hones melanoma niche focus”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
05/21/2021

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
Featured image for “Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “April 2025 Newsletter”
Apr. 16, 2025

April 2025 Newsletter

Featured image for “Update on the State of Vaccines for Melanoma”
Apr. 15, 2025

Update on the State of Vaccines for Melanoma

Featured image for “Healing Through Creativity: Art Therapy in Cancer Care”
Apr. 14, 2025

Healing Through Creativity: Art Therapy in Cancer Care

Featured image for “Side Effect Central: Lichen Planus Explained”
Apr. 14, 2025

Side Effect Central: Lichen Planus Explained

Featured image for “Behavioral Addiction Responsible for Excessive Indoor Tanning”
Mar. 31, 2025

Behavioral Addiction Responsible for Excessive Indoor Tanning

Filter by Tag